MedTrace Logo

This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

NCT07430592 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-02-27

No results posted yet for this study

Summary

The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.

Conditions

  • Malaria
  • Malaria Vivax
  • Radical Cure

Interventions

DRUG

SJ733/TQ placebo

SJ733 combined with Tafenoquine Placebo

DRUG

CQ/TQ Placebo

Chloroquine combined with Tafenoquine Placebo

DRUG

CQ/TQ

Chloroquine combined with Tafenoquine

DRUG

SJ733 (3-day)/TQ

SJ733 (3-day schedule) combined with Tafenoquine

DRUG

SJ733 (2-day ) /TQ

SJ733 (2-day schedule) combined with Tafenoquine

DRUG

SJ733(1-day)/TQ

SJ733 (1 day schedule) combined with Tafenoquine

Sponsors & Collaborators

  • Global Health Innovative Technology Fund

    collaborator OTHER

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • University of Minnesota

    collaborator OTHER

  • R. Kiplin Guy

    lead OTHER

Principal Investigators

  • Alejandro L Cuentas,, MD, PhD · Asociación Civil Selva Amazónica (ACSA), Iquitos, Loreto - Perú

  • Rodney K Guy, PhD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2028-11-20
Completion
2028-11-20
FDA Drug
Yes

Countries

  • Peru

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07430592 on ClinicalTrials.gov